American Spinal Injury Association

NeuroSolv Therapeutics Developing Spinal Cord Injury Therapy, Seeks Clinical Trial Investment

Retrieved on: 
星期二, 七月 11, 2023
Research, Finance, Consulting, Clinical Trials, Health Technology, Professional Services, Biotechnology, Pharmaceutical, Health, Science, Injection, Neuron, American Spinal Injury Association, Tetraplegia, Spinal cord, European Medicines Agency, Clinical trial, Multimedia, IP, Ventilation, Patient, Business Wire, Left, Biostatistics, Therapy, World Health Organization, Pharmaceutical industry, Medical device, Health insurance, Nursing

Data shared by the World Health Organization indicates that globally between 250,000 and 500,000 people are injured or diagnosed with a spinal cord injury each year.

Key Points: 
  • Data shared by the World Health Organization indicates that globally between 250,000 and 500,000 people are injured or diagnosed with a spinal cord injury each year.
  • Within the UK alone, there are 50,000 people living with a life-changing spinal cord injury according to the Spinal Injury Association.
  • The team is also looking to partner with spinal cord injury associations and sports injury organisations to bring awareness to advancements in treatments.
  • Aidan said: “There is a huge level of support and eagerness across the spinal cord injury community to advance recovery therapies.

NeuroSolv Therapeutics Developing New Therapy to Treat Spinal Cord Injury, Partners With AscellaHealth to Bring Therapy to Market

Retrieved on: 
星期二, 七月 11, 2023
Research, Surgery, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Injection, Neuron, Partnership, American Spinal Injury Association, Neuroplasticity, Tetraplegia, Spinal cord, Multimedia, Pharmacy, Ventilation, EMA, Patient, Synapse, European Medicines Agency, Therapy, World Health Organization, Pharmaceutical industry, Medical device, Dentistry, Health insurance

By temporarily removing the protective perineuronal net on the surface of spinal cord neurons, new synapses can be created.

Key Points: 
  • By temporarily removing the protective perineuronal net on the surface of spinal cord neurons, new synapses can be created.
  • In addition, the treatment removes signal-blocking glial scars on the surface of spinal cord neurons to enable new synapses to be made.
  • Within the UK alone, there are 50,000 people living with a life-changing spinal cord injury according to the Spinal Injury Association.
  • The team is also looking to partner with spinal cord injury associations and sports injury organisations to bring awareness to advancements in treatments.

Surgalign To Collaborate with Dr. Alexander Vaccaro and Dr. Pierce Nunley to Advance HOLO™ AI Insights and its Artificial Intelligence Technologies

Retrieved on: 
星期三, 五月 3, 2023
SRS, Surgeon, William H. Harris (orthopaedic surgeon), Population health, American Spinal Injury Association, LSU Health Sciences Center New Orleans, Thomas Jefferson University, North American Spine Society, American Academy of Orthopaedic Surgeons, Scoliosis Research Society, Spine, Intelligence, National Center for Spinal Disorders, Research, Biomarker, Associate, NASS, MRI, National library, Hospital, Publication, Medical director, Patient, OMICS Publishing Group, Principal, Artificial intelligence, TSN, AI, AAOS, Health, Orthopedic surgery, International Society, CSRS, Medical device

All of the parties involved are focused on using HOLO AI Insights with a goal to enhance clinical decision support and patient care through the use of artificial intelligence (AI).

Key Points: 
  • All of the parties involved are focused on using HOLO AI Insights with a goal to enhance clinical decision support and patient care through the use of artificial intelligence (AI).
  • HOLO AI Insights enables customers, partners, and clinical researchers to take advantage of the Company’s AI portfolio through a secure, highly scalable cloud platform for automated analysis of medical images.
  • Surgalign, in my opinion, is one of the most exciting given the groundbreaking work they are doing with artificial intelligence.
  • He is co-founder of The Spine Network (TSN), an organization dedicated to excellence and pioneering and integrating disruptive technologies, including AI, in Spine Research.

InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury

Retrieved on: 
星期四, 三月 9, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, SCI, Patient, Invivo Wines, Tetraplegia, Safety, PAETEC Holding Corp., Hope, American Spinal Injury Association, INSPIRE

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries (SCI), today announced topline results from the company’s INSPIRE 2.0 study, which was designed to evaluate the safety and probable benefit of InVivo’s investigational Neuro-Spinal Scaffold™, a bioresorbable scaffold-based device in development for patients with acute SCI.

Key Points: 
  • InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries (SCI), today announced topline results from the company’s INSPIRE 2.0 study, which was designed to evaluate the safety and probable benefit of InVivo’s investigational Neuro-Spinal Scaffold™, a bioresorbable scaffold-based device in development for patients with acute SCI.
  • The study did not meet its primary endpoint, which was assessed by the proportion of treated patients achieving an improvement of at least one American Spinal Injury Association (ASIA) Impairment Scale (“AIS”) grade at six months post-scaffold implantation, versus a control group that received standard of care surgery.
  • “We are disappointed by the outcome of this study as treatments for spinal cord injury are so urgently needed and we know many in the SCI patient and advocate community wait in hope for therapeutic options.
  • The company will also evaluate its strategic options and provide an update on corporate direction when appropriate.

NeuroAiD has shown favourable outcome in patients suffering from spinal cord injuries

Retrieved on: 
星期一, 六月 6, 2022
Use, Rehabilitation, American Spinal Injury Association, SCI, AES, Stroke, Journal, Neuroaid, DOI, Brain, Neurodegeneration, Pharmacology, Patient, AIS, Spinal cord injury, Brain damage, Quality of life, Survivor, Spine, Safety, Medical device, Medical imaging

Spinal cord injury (SCI) carries debilitating consequences with severe neurological and functional deficits, deteriorating the quality of life for survivors and their relatives.

Key Points: 
  • Spinal cord injury (SCI) carries debilitating consequences with severe neurological and functional deficits, deteriorating the quality of life for survivors and their relatives.
  • SATURN (Spinal cord injury Assessing Tolerability and Use of combined Rehabilitation and NeuroAiD) study was designed to evaluate the safety and potential role of NeuroAiD in subjects suffering from severe SCI.
  • NeuroAiD shows a favourable safety profile and promising benefits as an add-on therapy to patients suffering from severe spinal cord injuries.
  • Spinal cord injury assessing tolerability and use of combined rehabilitation and NeuroAiD (SATURN) study primary results of an exploratory study.

NeuroAiD has shown favourable outcome in patients suffering from spinal cord injuries

Retrieved on: 
星期一, 六月 6, 2022
Use, Rehabilitation, American Spinal Injury Association, SCI, AES, Stroke, Journal, Neuroaid, DOI, Brain, Neurodegeneration, Pharmacology, Patient, AIS, Spinal cord injury, Brain damage, Quality of life, Survivor, Spine, Safety, Medical device, Medical imaging

Spinal cord injury (SCI) carries debilitating consequences with severe neurological and functional deficits, deteriorating the quality of life for survivors and their relatives.

Key Points: 
  • Spinal cord injury (SCI) carries debilitating consequences with severe neurological and functional deficits, deteriorating the quality of life for survivors and their relatives.
  • SATURN (Spinal cord injury Assessing Tolerability and Use of combined Rehabilitation and NeuroAiD) study was designed to evaluate the safety and potential role of NeuroAiD in subjects suffering from severe SCI.
  • NeuroAiD shows a favourable safety profile and promising benefits as an add-on therapy to patients suffering from severe spinal cord injuries.
  • Spinal cord injury assessing tolerability and use of combined rehabilitation and NeuroAiD (SATURN) study primary results of an exploratory study.